Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Rates are also falling more among men than among women.
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
Men who have sex with men are at higher risk for the disease, which is driven by human papillomavirus.
A movement toward a greater focus on patient-reported outcomes is afoot.
A new classification system may more accurately reflect liver-related death trends in the United States.
Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.
People with liver cirrhosis often have substantial financial burden that interferes with their care.
The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.
A small study looked at response rates among those with HRAS-mutant head and neck carcinoma.
“To understand cancer better, we need the combination of chemistry, biology, chemical biology, computational biology and bioinformatics.”
This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.
Zenocutuzumab targets tumors with a specific genetic alteration, making it potentially active against cancer at multiple locations.
A novel drug that blocks multiple cancer-causing mutations shows promise, especially for combination therapy.
The findings could help identify patients who might benefit from combination therapy with a checkpoint blocker and another inhibitor.
Those diagnosed with liver cancer after an HCV cure had a 66% lower risk of death.
Research finds people treated outside of NCCN Guidelines recommendations had significantly higher direct costs.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.